论文部分内容阅读
目的:探讨复发性卵巢癌的细胞免疫治疗联合化疗治疗效果。方法:选取我院2013年2月~2016年1月期间收治的62例复发性卵巢癌患者,将其随机分为观察组(细胞免疫治疗联合化疗)和对照组(化疗)各31例,比较两组患者的各类免疫细胞水平变化及其生存期。结果:治疗前后两组患者的CD3+无显著变化(P>0.05)。治疗后两组患者的CD3-CD56+和CD19+水平显著上升(P<0.05)。其中观察组患者的CD3-CD56+[(14.46±10.03)%>(11.97±7.06)%]、CD19+[(12.18±10.01)%>(10.29±6.64)%]水平均高于对照组(P<0.05),观察组患者的PFS生存期[(15.31±8.01)月>(9.73±6.05)月]和OS生存期[(21.14±11.37)月>(12.29±9.02)月]明显高于对照组(P<0.05)。结论:细胞免疫治疗联合化疗治疗复发性卵巢癌的临床疗效显著,建议在临床上推广应用。
Objective: To investigate the effect of combined immunotherapy and chemotherapy with recurrent ovarian cancer. Methods: Totally 62 patients with recurrent ovarian cancer who were treated in our hospital from February 2013 to January 2016 were randomly divided into observation group (immunotherapy combined with chemotherapy) and control group (chemotherapy) with 31 cases each. Changes in the levels of various immune cells and their survival in both groups. Results: There was no significant difference in CD3 + between the two groups before and after treatment (P> 0.05). After treatment, the levels of CD3-CD56 + and CD19 + in both groups increased significantly (P <0.05). The levels of CD3-CD56 + [(14.46 ± 10.03)%> (11.97 ± 7.06)%] and CD19 + (12.18 ± 10.01)% (10.29 ± 6.64)% in the observation group were higher than those in the control group ). The PFS survival in observation group was significantly higher than that in control group [(15.31 ± 8.01) months> (9.73 ± 6.05) months] and OS (21.14 ± 11.37 months vs 12.29 ± 9.02 months) <0.05). Conclusion: The clinical curative effect of the combination of cell-mediated immunotherapy and chemotherapy in the treatment of recurrent ovarian cancer is significant. It is suggested that it should be popularized and applied clinically.